Skip to content

Investigating the topical effect of Ghost ( Costus Amorous) oil on the reduction of sexual desire in postmenopausal women

Investigating the effect of topical oil preparation of Ghost (Costus Amorous ) on the reduction of sexual desire in postmenopausal women compared to placebo: a double-blind randomized clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230730058969N1
Enrollment
110
Registered
2023-10-15
Start date
2023-09-23
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoactive sexual desire disorder. Hypoactive sexual desire disorder

Interventions

Intervention 1: Intervention group: receiving Tubi's Ghost oil product and apply topically twice a day and each time 20 drops on the pubic area in a back and forth massage for 5 minutes (superficial

Sponsors

Institute of Medical History, Islamic and Complementary Medicine Studies
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: Postmenopausal women between the ages of 40 and 65, who have been for a year since their last period, and complain of decreased sexual desire Completing the FSFI questionnaire and assessing the loss of sexual desire based on it, including a number equal to or less than 26 Menopause symptoms are not severe (less than 5), the score of the MSR questionnaire (menopause symptom severity) is 1 to 5 Having an emotionally satisfying relationship with a stable and sexually active spouse for at least the last 6 months Normal pelvic examination Having a wife who spends at least half of a month with the family At least 6 months have passed since the beginning of cohabitation Signing consent to participate in the project

Exclusion criteria

Exclusion criteria: Vaginal infection Vaginal bleeding The presence of a serious physical medical condition and a chronic illness that requires constant care Taking any chemical and herbal medicine known to affect libido Smoking and any substance abuse Disruption of a satisfactory emotional relationship with the spouse during the study

Design outcomes

Primary

MeasureTime frame
Sexual desire. Timepoint: At first, 2 week, 4week. Method of measurement: FSFI questionnaire.

Secondary

MeasureTime frame
Sexual arousal levels. Timepoint: At first, 2week, 4week. Method of measurement: FSFI questionnaire.;Vaginal lubrication levels. Timepoint: At first, 2 week ,4 week. Method of measurement: FSFI questionnaire.;Orgasm levels. Timepoint: At first, 2week ,4week. Method of measurement: FSFI questionnaire.;Satisfaction sexual levels. Timepoint: At first, 2week, 4week. Method of measurement: FSFI questionnaire.;Disparonia levels. Timepoint: At first, 2week, 4week. Method of measurement: FSFI questionnaire.;Sexual function. Timepoint: At first, 2week, 4week. Method of measurement: FSFI questionnaire.;Side effects of drugs. Timepoint: 2week and 4 week. Method of measurement: Medication side effects questionnaire.;BoBody temperament. Timepoint: At first and the end of study( after 4 weeks). Method of measurement: Body temperament questionnaire.;Severity of menopause symptom. Timepoint: At first and the end of study. Method of measurement: MSR questionnaire.;Severity of menopause. Timepoint: At first and end of study. Method of measurement: Menopause Rating Scale (MRS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkram Fallah

Iran University of Medical Sciences

Akram.fallah@gmail.com+98 21 2236 9560

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026